Related Experiment Video

Updated: Jun 27, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect

E Lara1, A Mai, V Calvanese

  • 1Cancer Epigenetics Laboratory, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.

Oncogene
|December 9, 2008
PubMed

Insights

Salermide, a novel compound, effectively targets Sirtuin 1 (Sirt1) and Sirtuin 2 (Sirt2) to induce cancer cell death. This Sirt1-dependent mechanism reactivates silenced proapoptotic genes, offering a promising anticancer therapeutic strategy.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Sirtuins (Sirt1 and Sirt2) are NAD+-dependent deacetylases linked to aging and cancer.
  • Targeting Sirtuins presents a potential strategy for anticancer drug development.

Purpose of the Study:

  • To investigate the anticancer potential of Salermide, a novel Sirt1 and Sirt2 inhibitor.
  • To elucidate the molecular mechanism underlying Salermide's antitumour activity.

Main Methods:

  • In vitro inhibition assays for Sirt1 and Sirt2.
  • In vivo studies in mice with human cancer cell lines.
  • Apoptosis induction analysis.
  • RNA interference for Sirt1 and Sirt2 knockdown.
  • p53 knockdown experiments.
  • Analysis of gene acetylation and expression.

Main Results:

  • Salermide demonstrated potent in vitro inhibition of Sirt1 and Sirt2.
  • The compound was well-tolerated in mice and induced tumour-specific apoptosis across various cancer cell lines.
  • Anticancer activity was mediated by Sirt1, not Sirt2, and was independent of p53.
  • Salermide reactivated epigenetically silenced proapoptotic genes in cancer cells.

Conclusions:

  • Salermide exhibits significant promise as an anticancer agent.
  • The drug's efficacy is attributed to Sirt1-mediated reactivation of proapoptotic genes, independent of p53.
  • This study provides mechanistic insights into Sirt1's role in tumorigenesis and anticancer therapy.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...